首页|药物球囊联合棘突球囊治疗冠脉分叉病变的临床效果

药物球囊联合棘突球囊治疗冠脉分叉病变的临床效果

扫码查看
目的 探讨药物球囊联合棘突球囊在冠脉分叉病变治疗中的临床效果。方法 选取宜春市人民医院2021年10月至2022年10月收治的50例冠脉分叉病变患者作为研究对象,按照随机数字表法分为对照组(25例)与观察组(25例),对照组采用支架植入联合普通球囊治疗,观察组采用支架植入联合药物球囊与棘突球囊治疗。比较两组的冠脉主支(MB)及分支(SB)治疗情况[参考血管直径(RVD)、最小管腔直径(MLD)、直径狭窄(DS)]、术后6个月血管晚期管腔丢失(LLL)情况以及术后6个月内分叉处支架内再狭窄与主要心血管不良事件(MACE)发生情况的差异。结果 观察组患者术后6个月MB的MLD高于对照组,差异有统计学意义(P<0。05);两组患者术毕和术后6个月MB的MLD高于本组术前,DS低于本组术前,差异有统计学意义(P<0。05)。观察组患者术后6个月SB的MLD高于对照组,DS低于对照组,差异有统计学意义(P<0。05);两组患者术毕和术后6个月SB的MLD高于本组术前,DS低于本组术前,差异有统计学意义(P<0。05)。观察组患者术后6个月MB与SB的LLL低于对照组,差异有统计学意义(P<0。05)。两组患者术后6个月内分叉处支架内再狭窄发生率比较,差异无统计学意义(P>0。05);两组患者术后6个月内MACE总发生率比较,差异无统计学意义(P>0。05)。结论 在冠脉分叉病变治疗中应用药物球囊联合棘突球囊能够提升治疗效果,改善病变管腔狭窄程度,降低LLL发生率。
Clinical effect of drug balloon combined with spinous process balloon in the treatment of coronary bifurcation lesions
Objective To explore the clinical effect of drug balloon combined with spinous process balloon in the treatment of coronary bifurcation lesions.Methods A total of 50 patients with coronary bifurcation lesions admitted to Yichun Peo-ple's Hospital from October 2021 to October 2022 were selected as the study subjects.They were divided into a control group(25 cases)and an observation group(25 cases)according to random number table method.The control group received stent implantation combined with conventional balloon therapy,while the observation group received stent implantation combined with drug balloon therapy and spinous process balloon therapy.The treatment outcomes of coronary major branch(MB)and secondary branch(SB)(reference vessel diameter[RVD],minimum lumen diameter[MLD],diameter stenosis[DS]),late lumen loss(LLL)at 6 months after surgery,and differences in stent restenosis and major cardiovascular adverse events(MACE)at the bifurcation within 6 months after surgery were compared between the two groups.Results The MLD of MB in the observation group at 6 months after surgery was higher than that in the control group,with a statistically significant dif-ference(P<0.05).The MLD of MB in the two groups of patients after surgery and 6 months after surgery were higher than those before surgery,while the DS of MB in the two groups were lower than those before surgery,with statistically significant differences(P<0.05).The MLD of SB in the observation group at 6 months after surgery was higher than that in the control group,while the DS was lower than that in the control group,with statistically significant differences(P<0.05).The MLD of SB in the two groups of patients after surgery and 6 months after surgery were higher than those before surgery,while the DS of SB in the two groups were lower than those before surgery,with statistically significant differences(P<0.05).The LLL of MB and SB in the observation group at 6 months after surgery were lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of in-stent restenosis at the bifurcation within 6 months after surgery between the two groups of patients(P>0.05).There was no statistically signifi-cant difference in the total incidence of MACE between the two groups of patients within 6 months after surgery(P>0.05).Conclusion The application of drug balloon combined with spinous process balloon in the treatment of coronary bifurcation lesions can improve the treatment effect,improve the degree of stenosis of the lesion lumen,and reduce the incidence of LLL.

Coronary bifurcation lesionsDrug balloonSpinal process balloonLate stage luminal lossMajor adverse car-diovascular events

张永庚、姜玲、李敏

展开 >

江西省宜春市人民医院心血管内科,江西宜春 336000

江西省宜春市人民医院内分泌代谢科,江西宜春 336000

江西省宜春市人民医院医学影像科,江西宜春 336000

冠脉分叉病变 药物球囊 棘突球囊 晚期管腔丢失 主要不良心血管事件

江西省卫生健康委科技计划项目

202212666

2024

中国当代医药
中国保健协会 当代创新(北京)医药科学研究院

中国当代医药

影响因子:1.215
ISSN:1674-4721
年,卷(期):2024.31(7)
  • 27